Inj, ziv-aflibercept, 1mg
Products billed under this code include Zaltrap.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Zaltrap.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Zaltrap | Sanofi-Aventis U.S. LLC | 00024-5840-01 | 100 | $970.20 |
| Zaltrap | Sanofi-Aventis U.S. LLC | 00024-5841-01 | 200 | $1,940.40 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $9.702 | +$1.028 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted September 17, 2026 |
| 3Q26 | $8.674 | +$0.066 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted September 15, 2026 |
| 2Q26 | $8.608 | +$1.384 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted September 15, 2026 |
| 1Q26 | $7.224 | −$0.656 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted September 15, 2026 |
| 4Q25 | $7.88 | −$0.099 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted September 8, 2026 |
| 3Q25 | $7.979 | −$0.319 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted March 10, 2026 |
| 2Q25 | $8.298 | +$0.314 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted March 10, 2026 |
| 1Q25 | $7.984 | +$1.48 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted December 19, 2025 |
| 4Q24 | $6.504 | −$0.587 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted June 11, 2025 |
| 3Q24 | $7.091 | +$0.409 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted June 11, 2025 |
| 2Q24 | $6.682 | −$0.60 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted March 11, 2025 |
| 1Q24 | $7.282 | −$0.524 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted December 19, 2024 |
| 4Q23 | $7.806 | +$0.994 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted October 10, 2024 |
| 3Q23 | $6.812 | −$0.577 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted June 5, 2024 |
| 2Q23 | $7.389 | +$0.383 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted February 23, 2024 |
| 1Q23 | $7.006 | −$0.121 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted December 6, 2023 |
| 4Q22 | $7.127 | −$0.964 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted June 22, 2023 |
| 3Q22 | $8.091 | −$0.131 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted June 9, 2023 |
| 2Q22 | $8.222 | +$0.561 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted December 14, 2022 |
| 1Q22 | $7.661 | −$0.759 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted June 8, 2022 |
| 4Q21 | $8.42 | +$0.151 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted June 2, 2022 |
| 3Q21 | $8.269 | +$0.746 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted June 2, 2022 |
| 2Q21 | $7.523 | −$0.973 | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted March 1, 2022 |
| 1Q21 | $8.496 | – | 1 MG | Inj, ziv-aflibercept, 1mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.